Bupivacaine/Epinephrine

Phase 2Small molecule

WWashington University School of Medicine

Bupivacaine/Epinephrine is one of 5 small molecule programs targeting Local Anesthesia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Local AnesthesiaRecruiting

Local AnesthesiaPhase 2

Recruiting

Competition

Competitive Landscape

4 competitors in Local Anesthesia

#DrugCompanyPhaseTrials

Ketalar

AAultman Health Foundation

Approved

1 2

Benadryl

PParkedale

Phase 3

1 3

Oraverse

NNovocol Pharmaceutical of Canada, Inc.

Phase 3

1 4

Bupivacaine/Epinephrine

WWashington University School of Medicine

Phase 2

1 5

Lidocaine Epinephrine

KKythera Biopharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Local Anesthesia

NCT06429501

Clinical

Trials by Indication[1]

Local Anesthesia1 trial

Local Anesthesia for Facial Fractures

Recruiting·WWashington University School of Medicine·Phase 2·NCT06429501·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Bupivacaine/Epinephrine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bupivacaine/Epinephrine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bupivacaine/Epinephrine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Washington University School of Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: WWashington University School of Medicine

Bupivacaine/Epinephrine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Local Anesthesia1 trial

References

Drug Info

Quick Facts

Related News